Personalized 177Lu-Octreotate Peptide Receptor Radionuclide Therapy (PRRT) Allows a Safe and Significant Increase of Radiation Dose to Neuroendocrine Tumors (NETs) Abstract #1534

Introduction: 177Lu-octreotate PRRT is commonly administered at fixed/empiric activity per cycle, which results in highly variable radiation doses to critical organs and undertreatment of the majority of patients.
Aim(s): To assess the potential of personalized PRRT to safely increase absorbed radiation dose rate to tumors.
Materials and methods: Twelve NET patients underwent four 177Lu-octreotate induction cycles followed by quantitative SPECT dosimetry. The median activity per cycle was 7.4 (5.6–8.1) GBq. We simulated a personalized PRRT protocol where activity per cycle was adjusted to reach, over 4 cycles, cumulative doses of 23 Gy to the kidney or 2 Gy to the bone marrow (BM), the generally recognized safe dose thresholds.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Michela Del Prete

To read results and conclusion, please login ...

Further abstracts you may be interested in

#161 Low Dose Multiple Cycle (LD/MT) Peptide Receptor Radionuclide Therapy: a new concept for the treatment of well-differentiated metastatic neuroendocrine tumors
Introduction: It has been shown experimentally that low dose radiation can effectively kill slow growing cancer cells. Also, external beam radiation therapy applies a fractionated delivery of radiation dose to reduce toxicity with equal or even better therapeutic efficacy.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Vikas Prasad
#301 Medical and Peptide Receptor Radionuclide Therapy (PRRT) with Somatostatin Analogues (SSA) in Well- and Moderately Differentiated Neuroendocrine Tumors
Introduction: PRRT is a treatment choice for inoperable or metastasized neuroendocrine tumors and this therapy seems more effective in the biochemical and volume control of disease than SSA alone.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Prof Laura De Marinis
#395 Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) in North American Cohort of Patients with Metastatic Well-Differentiated Neuroendocrine Tumors (mNETs)
Introduction: PRRT is an accepted treatment in Europe for patients (pts) with mNETs, but considered investigational in the USA.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Boris Naraev
#439 Chromogranin A (CgA) and Pancreastatin (PcSt) as Predictors of Peptide Receptor Radionuclide Therapy (PRRT) Outcomes in Patients with Metastatic Well-Differentiated Neuroendocrine Tumors (mNETs)
Introduction: CgA and PcSt are widely used in assessing response to treatment in mNETs.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Nancy Sharma
#817 Surgery after Peptide Receptor Radionuclide Therapy (PRRT) in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
Introduction: There are a few case reports on surgery after peptide receptor radionuclide therapy (PRRT).
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Surgical treatment
Presenting Author: Emilio Bertani
Authors: Bertani E, Chiappa A, Fazio N, Grana C, ...